Purpose: Intimal hyperplasia and graft thrombosis are major causes of graft failure. Heparin prolongs graft patency and inhibits neointimal hyperplasia in animal models. The purpose of this study was to evaluate the effect of a heparin-coated expanded polytetrafluoroethylene (ePTFE) graft on platelet deposition and anastomotic neointimal hyperplasia after aortoiliac bypass grafting in a baboon model. Methods: Heparin-coated ePTFE grafts (4-mm diameter) were incorporated into exteriorized femoral arteriovenous shunts placed in five baboons. Platelet deposition was analyzed by measuring the accumulation of indium 111-labeled platelets on the grafts, with dynamic scintillation camera imaging. Eight adult male baboons (mean weight, 9.3 kg) underwent bilateral aortoiliac bypass grafting with ePTFE grafts (4-mm internal diameter). In each animal a heparincoated ePTFE graft was placed in one aortoiliac artery, and an uncoated graft, which served as the control, was placed in the contralateral aortoiliac artery. All grafts were harvested at 4 weeks, and were analyzed quantitatively for neointimal hyperplasia at graft-vessel anastomoses. Results: Early platelet deposition on heparin-coated grafts after 1 to 4 hours of ex vivo circuitry was significantly reduced. All the harvested aortoiliac grafts were patent at 4 weeks. There was a significant reduction in neointimal area at both proximal (0.26 ؎ 0.11 mm 2 ) and distal (0.29 ؎ 0.14 mm 2 ) anastomoses in the heparin-coated grafts, compared with proximal (0.56 ؎ 0.18 mm 2 ) and distal (0.63 ؎ 0.21 mm 2 ) anastomoses in the untreated control grafts (P < .05). In addition, neointimal cell proliferation assayed with bromodeoxyuridine (BrdU) incorporation was reduced in the graft neointima (3.47% ؎ 0.43%) in heparin-coated grafts compared with the graft neointima (6.21% ؎ 0.59%) in untreated control grafts (P < .05). Surg 2004;39:1322-8.) Clinical Relevance: An autologous vein graft is the ideal bypass conduit in peripheral arterial reconstruction; however, many patients who undergo bypass grafting do not have adequate or available autologous vein graft. As a result surgeons often must rely on prosthetic grafts as an alternative conduit in arterial bypass procedures. Clinical outcomes with prosthetic grafts in peripheral arterial reconstruction are generally inferior to those with autologous vein bypass grafts, in part because of anastomotic neointimal hyperplasia. This study evaluated the effect of small-caliber heparin-coated expandable polytetrafluoroethylene (ePTFE) grafts in aortoiliac reconstruction in a baboon model. The study found that heparin-ciated ePTFE grafts resulted in less intimal hyperplasia and less platelet deposition after implantation, compared with noncoated control ePTFE grafts.
It is widely accepted that an autologous vein graft is the ideal bypass conduit in peripheral arterial bypass procedures. However, nearly a third of patients who undergo peripheral arterial reconstructive operations do not have adequate or available autologous vein graft, as a result of either previous vein harvest or poor vein quality. 1 Under such circumstances surgeons may have to rely on prosthetic grafts, such as expanded polytetrafluoroethylene (ePTFE) grafts, as an alternative conduit in arterial bypass procedures.
Clinical outcomes with prosthetic grafts in peripheral arterial reconstruction are generally inferior to those with autologous vein bypass grafts, in part because of anastomotic neointimal hyperplasia. 2 No doubt the strategy to reduce anastomotic neointimal hyperplasia after prosthetic bypass surgery is critically important to improve the clinical outcome of vascular reconstruction.
One pharmacologic agent that has received wide research focus as a means to reduce neointimal hyperplasia is heparin, which is a mucopolysaccharide found in most tissues. Heparin inhibits thrombin and activated factors IX, X, XI, and XII, which are involved in the conversion of prothrombin to thrombin, thereby reducing thrombin formation. In addition, heparin has a potent antiproliferative effect on vascular smooth muscle cells (SMCs), and this effect is independent of its anticoagulant activity. 3, 4 Its inhibitory effect on SMCs is mediated in part through interactions with cell receptors, growth factors, adhesion molecules, and proteinase inhibitors. 5 In models of endothelial denudation in the rat, sustained heparin infusions decreased neointimal thickening by 40% to 50%. 3, 4, 6, 7 Our laboratory previously demonstrated that local infusion of heparin in aortoiliac bypass grafting significantly reduced anastomotic neointimal hyperplasia in a baboon model. 8 We also recently reported the benefit of heparin-coated stents in reducing neointimal hyperplasia after iliac and carotid artery placement in baboons. 9, 10 The objective of this study was to assess the effect of heparin-coated PTFE grafts on neointimal hyperplasia after prosthetic arterial reconstruction. We hypothesized that the coating of a PTFE graft with heparin would provide a biocompatible surface for the graft that limits anastomotic neointimal hyperplasia. This study quantitatively analyzed the neointimal thickness, neointimal area, and cell proliferation in the heparin-coated ePTFE grafts and uncoated control grafts after aortoiliac reconstruction in a baboon model.
MATERIAL AND METHODS
Heparin coating of ePTFE grafts. Standard ePTFE grafts (internal diameter, 4 mm; length, 5 cm; Gore-Tex; W. L. Gore and Associates, Flagstaff, Ariz) were used in our study for heparin coating. The luminal surface of the graft was first coated with the Carmeda bioactive surface, followed by sequential polymer layered coating. The next layer was polyethyleneimine (PEI) cross-linked with glutaraldehyde. This provided a positively charged surface on which dextran-sulfate was ionically bound. On the negatively charged dextran sulfate layer, another layer of PEI was ionically bound. This second PEI layer provided a free amino group, which was used to bind heparin through an aldehyde group on the heparin. The heparin was modified to contain the free aldehyde moiety with the technique described previously. 11, 12 With this single-point attachment method the heparin active site was available for binding anti-thrombin III (AT-III) and contained catalytic function. The grafts were sterilized with ethylene oxide. The post-ethylene oxide sterilization heparin activity and concentration were approximately 53 pm AT-III uptake/ cm 2 and 15 mg/cm 2 , respectively. These graft preparation procedures were competed at W. L. Gore & Associates.
Platelet deposition in an exteriorized arteriovenous shunt model. Platelet deposition was analyzed with an exteriorized femoral arteriovenous shunt system, which was surgically established in five baboons. This method of platelet deposition analysis has been well-characterized in our laboratory. 13, 14 In brief, this ex vivo shunt system consists of two 5-cm lengths of silicone rubber tubing (3.0-mm diameter). Blood flow, established by connecting the two silicone rubber shunt segments, was adjusted to 100 mL/ min. A PTFE segment was interposed between the arms of the permanent arteriovenous shunt. Platelet deposition was measured in real time with scintillation camera imaging of indium 111-labeled platelets. Autologous baboon platelets were labeled with 1 mCi of indium oxide ( 111 In) and reinjected at least 1 hour before imaging, when 111 Inlabeled platelets were functionally normal. Gamma camera images of vascular grafts were acquired continuously and separately for 4 hours at 10-minute intervals, with a GE 400T scintillation camera (General Electric, Milwaukee, Wis). The data were stored and analyzed on a Medical Data System A3 Computer. A medium-energy collimator was placed close to the animal. Measurements of 111 In activity were corrected for background activity.
Activity of a 5-mL whole blood standard was also determined. The activity of the blood standard was also corrected for the small fraction of circulating nonplatelet radioactivity, to give platelet-associated 111 In activity per milliliter of whole blood. The total numbers of deposited platelets in the heparin-coated or control grafts were calculated by dividing the deposited platelet activity (counts per minute) by the circulating blood activity (counts ϫ minutes Ϫ1 ϫ mL Ϫ1 ) and multiplying by the circulating platelet count (platelets per milliliter). The results were expressed as platelets deposited per 1 cm of vascular graft. Platelet deposition was analyzed between heparin-coated ePTFE grafts and noncoated control grafts. Aortoiliac bypass graft model in baboons. Eight male baboons (Papio cynocephalus) weighing 9.4 to 13.3 kg (mean, 12.9 kg) were used in the study. All animals had been quarantined and observed to be disease-free for at least 90 days. All procedures and care were performed in accordance with the Guideline for the Care and Use of Laboratory Animals (National Institutes of Health Publ. No. 80-23, revised 1985) and the Food and Drug Administration Good Laboratory Practice for Non-clinical Laboratory Studies Regulations (21 CFR, Part 58). Prophylactic cefazolin (1 g; Kefzol; Marsam Pharmaceuticals, Cherry Hill, NJ) was administered intravenously. Animals were given thiopental sodium (10 mg/kg) intravenously (Pentothal; Abbott Laboratories, North Chicago, Ill). Endotracheal intubation was performed, and anesthesia was maintained with 1% isoflurane (Rhone-Poulenc, Bristol, England). All animals received intravenous heparin (100 U/kg) at the time of the operation. Bilateral aortoiliac bypass grafting was performed, with heparin-coated ePTFE grafts placed on one side and noncoated control grafts placed on the contralateral side, in a baboon model, as previously described. 8, 15 Heparin-coated versus control grafts were randomly alternated between right and left aortoiliac segments (Fig 1) . No anticoagulant medications were administered postoperatively. Animals were killed and the grafts harvested at 4 weeks for analysis.
Histologic and morphometric analysis. Bromodeoxyuridine (BrdU; Sigma, St Louis, Mo), 50 mg/kg dissolved in 50 mL of normal saline solution, was administered subcutaneously 24 hours before death at 28 days. Grafts and adjacent 3-cm segments of attached vessel at each anastomosis were harvested and fixed in 10% buffered formalin (Baxter Diagnostics, McGaw Park, Ill). After fix-ation, the grafts were embedded in paraffin and sectioned at the midpoint between the heel and toe of each anastomosis at a distance of 2 mm from the heel of each anastomosis and at 5-mm intervals along the entire graft length. Five-micron sections were cut and stained with hematoxylin-eosin and Verhoeff-Masson stains. Cell ingrowth overlying the luminal surface of the graft adjacent to the anastomosis was considered graft neointima, and cell proliferative tissue overlying the internal elastic lamina of native vessels was considered vessel neointima. Morphometric measurements of the area of anastomotic neointima were performed with computer image analysis software (Optimas; Bioscan, Edmonds, Wash) on a magnified image relayed from a microscope-mounted video camera to a digitizing pad and video monitor (Thomas Optical, Columbus, Ga), as previously described. 8, 16 The graft and native vessel neointimal tissues at the anastomoses were measured separately. Three tissue blocks were generated between the heel and toe of each anastomosis. From the three tissue blocks, mean values of morphometric measurements and cell proliferation rates were reported. All tissue samples were analyzed in a blinded manner with respect to whether they were derived from heparin-coated or control grafts.
Immunocytochemistry. The avidin-biotin complex immunoperoxidase procedure (LSAB Kit; Dako, Carpenteria, Calif) was used to identify determinants that characterized neointimal cell types and proliferating cells, as described. 8, 16 In brief, immunostaining for ␣-actin and factor VIII-related antigen was performed to identify SMCs and endothelial cells, respectively. Proliferating cells were identified with anti-BrdU monoclonal antibody (Dako). BrdUpositive cells were quantified manually with a cell-counting technique on a calibrated micrometer grid with microscopy (ϫ400). In each field, all cells were counted, and the number of positively stained cells was expressed as a percentage of total cells, to arrive at the BrdU index. A minimum of 10 fields per section were quantified.
Statistical analysis. All statistical analysis was performed with a statistical software program (SAS Institute, Cary, NC). Comparisons of neointimal areas and cell proliferation between the heparin-treated grafts and the control grafts were made with the Student t test (two-tailed) for paired data. Comparisons of hematologic measurements at various time points were made with analysis of variance. Values are given as mean Ϯ SE. The results were considered significant at P Ͻ .05.
RESULTS
Platelet deposition. There were significant differences in platelet deposition after 40 minutes between the heparin coated and control grafts. Significant reduction in platelet deposition was noted at all time points from 1 to 4 hours for heparin-coated grafts compared with noncoated control grafts (P Ͻ .01; Table I ).
Anastomotic neointimal hyperplasia. All animals survived the duration of the study, and all aortoiliac grafts remained patent at tissue harvesting. Measurable neointimal hyperplasia was present at both proximal and distal anastomoses in both the noncoated control grafts and the heparin-coated grafts. SMCs were the major type of anastomotic neointimal cells identified at ␣-actin immunostaining. Endothelial cells covered the surfaces of all of the anastomotic neointimas as shown with factor VIII-related antigen immunostaining. The results regarding anastomotic neointimal hyperplasia for the control and heparincoated grafts are shown in Table II . There was a significant reduction of graft neointimal area at both proximal (0.26 Ϯ 0.11 mm 2 ) and distal (0.29 Ϯ 0.14 mm 2 ) anastomoses in the heparin-coated grafts, as compared with proximal (0.56 Ϯ 0.18 mm 2 ) and distal (0.63 Ϯ 0.21 mm 2 ) anastomoses in the untreated control grafts (P Ͻ .05). In contrast, no significant difference was noted in vessel neointimal area and thickness between the two graft groups. Representative sections of the proximal and distal anastomoses of the two graft groups are shown in Figs 2 and 3, respectively. Neointimal cell proliferation. Neointimal cell proliferation was evaluated with BrdU incorporation staining. SMCs were the major type of anastomotic neointimal cells identified with ␣-actin immunostaining. Endothelial cells covered the surfaces of all of the anastomotic neointima, as demonstrated with factor VIII-related antigen immunostaining. No significant difference in neointimal BrdU labeling index between proximal and distal anastomoses of grafts was found. When comparing the cell proliferation of graft neointima between the control and heparin-coated grafts, the BrdU labeling index was significantly smaller (P Ͻ .05; Table III ) in the heparin-coated grafts (3.47 Ϯ 0.43%) as compared with the control grafts (6.21% Ϯ 0.59%). However, the difference in BrdU labeling index in the native vessel at the anastomoses was not significant between the treated and control groups (5.73% Ϯ 0.56% vs 4.81% Ϯ 0.63%, respectively; P Ͼ .5). The data show that heparin-coated grafts significantly reduced cell proliferation in the graft neointimal region, but exerted no significant effects in the native neointimal tissues.
DISCUSSION
Although autologous vein graft is the ideal bypass conduit in peripheral arterial bypass procedures, it is frequently unavailable as a result of previous harvest or poor vein quality in many patients who undergo a peripheral arterial bypass procedure. Many alternative bypass conduits have received wide research focus with regard to their thrombogenic propensity and patency rate after vascular reconstruction. Among them, ePTFE graft is the most commonly used alternative bypass conduit when an autologous vein graft is not available. In clinical studies, ePTFE grafts have performed reasonably well in large and mediumsized arteries, but have had limited success in vessels with diameter less than 6 mm, because of early graft occlusion. 17, 18 The primary patency rates at 4 years for ePTFE infrapopliteal grafts and aortocoronary grafts are only 12% and 14%, respectively. [19] [20] [21] Early graft occlusion from thromobosis and late graft failure from neointimal hyperplasia are two major challenges in small-caliber prosthetic vascular reconstruction.
Neointimal hyperplasia is a complicated cellular and molecular response to mechanical vascular injury. This response is characterized by SMC proliferation, migration, and extracellular matrix production, with the final result being vessel wall thickening and luminal narrowing. In addition, this complex event may be accelerated in part as a consequence of factors related to compliance mismatch, endothelial dysfunction, ongoing platelet deposition, monocyte recruitment, and chronic inflammatory reactions. Therefore new strategies that target these pathways may ultimately improve patency rates for small-caliber ePTFE grafts in human beings.
Our current understanding with regard to the pathogenesis of intimal hyperplasia is largely based on experimental models of balloon denudation injury, surgical endarterectomy, and prosthetic bypass grafting. These experimental evaluations of intimal hyperplasia have been studied extensively in small animal models such as rats and rabbits. Studies of intimal hyperplasia in larger primate animal models, in contrast, are considerably scarce, but they may have greater relevance to recurrent stenosis seen in the clinical setting. This is due in part to the similar vessel architecture and hemodynamics of the primate model compared with human beings. The present study examined the short-term platelet deposition of small-caliber heparincoated ePTFE grafts and the patency rate after aortoiliac bypass graft in baboons, which exhibit a high degree of genetic similarity with human beings. Platelet deposition was analyzed by measuring 111 In-radiolabeled platelet activity, and neointimal hyperplasia was assessed with morphometric analysis, which provided a detailed comparison of the vessel wall architecture with respect to the intimal and medial thickness.
We found that heparin-coated ePTFE grafts resulted in reduced platelet deposition, compared with noncoated control grafts. The thromboresistant mechanisms of heparin relate to its interaction with AT-III, resulting in ATheparin complex, which accelerates the inactivation of thrombin and other coagulation factors. 20 The formation of an AT-heparin complex inhibits heparin-induced platelet aggregation. 22 Similar thromboresistant benefits of heparin surface coating in reducing platelet activation and deposition have been demonstrated in various clinical devices, including hemodialysis filters and intravascular stents, and cardiopulmonary bypass circuitry. [23] [24] [25] Our study also showed that heparin-coated ePTFE grafts resulted in significantly less anastomotic neointimal hyperplasia, compared with noncoated grafts, as evidenced by reduced cell proliferation and medial thickness. The antiproliferative activity of heparin has been proven in baboon, human, rat, and bovine SMC cultures. 26, 27 Administration of heparin in vitro inhibits SMC proliferation by inhibiting DNA synthesis and by limiting the transcription gene necessary for cell passage from G 0 through G 1 and into the S phase. 28, 29 Research investigations have also focused on other possible mechanisms by which heparin inhibits neointimal proliferation. For example, the antiproliferative properties of heparin may in part be mediated through inhibition of a second messenger pathway, resulting in proto-oncogene expression in cell cycling. 30 Heparin not only inhibits intracellular protein kinase activity during signal transduction, 31 it also downregulates transcription activator pro-teins. 32 Moreover, it can modulate the function and expression of numerous growth factors. Heparin can inhibit basic fibroblast growth factor-mediated growth responses of both endothelial and smooth muscle cells, and downregulate basic fibroblast growth factor expression in the wall of injured arteries. 33 Heparin also inhibits epidermal growth factor receptor expression, and potentiates the inhibitory properties of transforming growth factor-␤ by releasing it from a carrier protein. 34, 35 In addition, heparin selectively inhibits the production of certain proteases critical for degrading extracellular matrix, which can diminish cellular proliferation. These proteases include tissue-type plasminogen activator, interstitial collagenase, stromelysin, and gelatinase. 36 All things considered, heparin has a crucial role in modulating SMC migration and neointimal proliferation via a complex biochemical and cellular cascade.
We previously reported the beneficial effect of heparin in improving graft patency in small-caliber ePTFE bypass grafts. 8 In that study local infusion of heparin with an osmotic pump attached to the ePTFE graft after aortoiliac bypass significantly reduced anastomotic neointimal hyperplasia. We also reported similar improved patency rates in heparin-coated balloon-expandable stents compared with noncoated stents after carotid and iliac artery placement in baboons. 9, 10 Although these antiproliferative properties of heparin in animal experiments represent potential treatment strategies for recurrent stenosis, these beneficial effects of heparin have not been demonstrated consistently in clinical trials of coronary balloon angioplasty. 37, 38 Moreover, the systemic infusion of heparin failed to reduce intimal hyperplasia in a baboon angioplasty model, even at concentrations previously effective in inhibiting baboon SMC proliferation in culture. 39 Several explanations may account for the observed disparity in heparin effects, including variations in heparin preparation, differences in route and duration of heparin delivery, varying degrees of arterial injuries, and interspecies differences in SMC proliferation. In human beings and primates, the therapeutic heparin dose for inhibiting SMC proliferation may be quantitatively increased compared with the heparin requirement in nonprimate smaller animals.
In summary, small-caliber heparin-coated ePTFE grafts result in less platelet deposition after implantation in an exteriorized femoral circulation in baboons, when compared with noncoated grafts. In addition, heparin-coated grafts inhibited SMC proliferation and anastomotic neointimal hyperplasia at 4 weeks after aortoiliac bypass grafting, compared with noncoated grafts. Our results suggest that small caliber heparin-coated ePTFE grafts may represent a useful therapeutic strategy to improve graft patency in small-diameter prosthetic vascular reconstruction.
